Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration

被引：15

作者：

Ahmadieh H. ^{[1
]}

Taei R. ^{[1
]}

Soheilian M. ^{[1
]}

Riazi-Esfahani M. ^{[2
,3
]}

Karkhaneh R. ^{[2
]}

Lashay A. ^{[2
]}

Azarmina M. ^{[1
]}

Dehghan M.H. ^{[1
]}

Moradian S. ^{[1
]}

机构：

[1] Ophthalmic Research Center, Shaheed Beheshti Medical University, Labbafinejad Medical Center, Tehran

[2] Farabi Eye Hospital, Tehran

[3] Noor Eye Clinic, Tehran

来源：

BMC Ophthalmology | / 7卷 / 1期

关键词：

Bevacizumab; Optical Coherence Tomography; Triple Therapy; Fluorescein Angiography; Best Correct Visual Acuity;

D O I：

10.1186/1471-2415-7-10

中图分类号：

学科分类号：

摘要：

Background. To evaluate the efficacy of triple therapy consisting of single-session photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone (IVT) as initial pulse therapy followed by repeat intravitreal bevacizumab injections for maintenance treatment in neovascular age-related macular degeneration (AMD). Methods. In a prospective interventional case series, patients with subfoveal choroidal neovascularization (CNV) secondary to AMD underwent pulse therapy with single-session PDT according to the standard protocol followed by 1.25 mg IVB and 2 mg IVT 48 hours later. Best corrected visual acuity (BCVA) was assessed and optical coherence tomography (OCT) and fluorescein angiography (FA) were performed prior to treatment. BCVA and OCT measurements were repeated at 6 week intervals and FA was obtained after 12 weeks and when necessary thereafter. Repeat injections of IVB were performed based on fluorescein angiographic evidence of CNV leakage. Results. This series included 17 eyes of 17 patients with mean age of 67.6 ± 7.2 years. Mean follow up duration was 50.4 ± 15.5 weeks. Mean BCVA prior to treatment was 0.74 ± 0.33 logMAR which improved to 0.52 ± 0.36 logMAR after 12 weeks (P = 0.012) and 0.41 ± 0.38 logMAR after 24 weeks (P = 0.001). Mean pretreatment central macular thickness (CMT) was 395 ± 181μ which was significantly reduced to 217 ± 69μ (P = 0.005), 231 ± 79μ (P = 0.028) and 221 ± 87μ (P = 0.05) six, twelve and twenty-four weeks after initial treatment respectively. Visual acuity improvement and CMT reduction was maintained during the follow-up period. IVB injections were repeated once, twice and three times in 10, 7 and 2 eyes at a mean interval of 20.2 ± 10.1, 19 ± 13.7 and 15 ± 1.4 weeks after initial therapy, respectively. Conclusion. Initial pulse triple therapy consisting of single-session PDT combined with IVB and IVT improves vision and reduces CMT in neovascular AMD. Repeat IVB injections maintain the visual gain from the initial combination therapy. © 2007 Ahmadieh et al; licensee BioMed Central Ltd.

引用

共 27 条

[1]

Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials- TAP report 1, Arch Ophthalmol, 117, pp. 1329-1345, (1999)

[2]

Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials- TAP report 2, Arch Ophthalmol, 119, pp. 198-207, (2001)

[3]

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two- year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization- Verteporfin in Photodynamic Therapy Report 2, Am J Ophthalmol, 131, pp. 541-560, (2001)

[4]

Schlotzer-Schrehardt U., Viestenz A., Naumann G.O., Laqua H., Michels S., Schmidt-Erfurth U., Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes, Graefes Arch Clin Exp Ophthalmol, 240, pp. 748-757, (2002)

[5]

Schmidt-Erfurth U., Michels S., Barbazetto I., Laqua H., Photodynamic effects on choroidal neovascularization and physiological choroid, Invest Ophthalmol Vis Sci, 43, pp. 830-841, (2002)

[6]

Michels S., Schmidt-Erfurth U., Sequence of early vascular events after photodynamic therapy, Invest Ophthalmol Vis Sci, 44, pp. 2147-2154, (2003)

[7]

Schmidt-Erfurth U., Niemeyer M., Geitzenauer W., Michels S., Time course and morphology of vascular effects associated with photodynamic therapy, Ophthalmology, 112, pp. 2061-2069, (2005)

[8]

Wang Y.S., Friedrichs U., Eichler W., Hoffmann S., Wiedemann P., Inhibitory effects of triamcinolone acetonide on bFGF - Induced migration and tube formation in choroidal microvascular endothelial cells, Graefes Arch Clin Exp Ophthalmol, 240, pp. 42-48, (2002)

[9]

Danis R.P., Ciulla T.A., Pratt L.M., Anliker W., Intravitreal triamcinolone acetonide in exudative age- related macular degeneration, Retina, 20, pp. 244-250, (2000)

[10]

Gillies M.C., Simpson J.M., Luo W., Penfold P., Hunyor A.B., Chua W., Mitchell P., Billson F., A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: One-year results, Arch Ophthalmol, 121, pp. 667-673, (2003)

← 1 2 3 →